The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients

Peritoneal Dialysis International

Volumn 29, Issue 5, 2009, Pages 562-567

  Young, Daniel O ^a   Cheng, Steven C ^a   Delmez, James A ^a   Coyne, Daniel W ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic kidney disease; Hyperphosphatemia; Niacin; Niacinamide; Nicotinamide; Phosphorus; Renal osteodystrophy; Secondary hyperparathyroidism

Indexed keywords

CINACALCET; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINAMIDE; PHOSPHORUS; PLACEBO; TRIACYLGLYCEROL; VITAMIN D; VITAMIN B COMPLEX;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERPHOSPHATEMIA; LEUKOCYTE COUNT; LIPID ANALYSIS; MALE; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; BLOOD; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERPHOSPHATEMIA; MALE; MIDDLE AGED; NIACINAMIDE; PERITONEAL DIALYSIS; PHOSPHORUS; VITAMIN B COMPLEX;

EID: 73949143510     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.1177/089686080902900515     Document Type: Article

References (12)

1. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(4 Suppl 3):S1-201.
2. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000; 35:1226-37.
3. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31:607-17.
4. Katai K, Tanaka H, Tatsumi S, Fukunaga Y, Genjida K, Morita K, et al. Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine. Nephrol Dial Transplant 1999; 14:1195-201.
5. Takahashi Y, Tanaka A, Nakamura T, Fukuwatari T, Shibata K, Shimada N, et al. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int 2004; 65: 1099-104.
6. Sampathkumar K, Selvam M, Sooraj YS, Gowthaman S, Ajeshkumar RN. Extended release nicotinic acid-a novel oral agent for phosphate control. Int Urol Nephrol 2006; 38:171-4.
7. Muller D, Mehling H, Otto B, Bergmann-Lips R, Luft F, Jordan J, et al. Niacin lowers serum phosphate and increases HDL cholesterol in dialysis patients. Clin J Am Soc Nephrol 2007; 2:1249-54.
8. Cheng SC, Young DO, Huang Y, Delmez JA, Coyne DW. A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3:1131-8.
9. Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem 1955; 54: 558-9.
10. Manns B, Stevens L, Miskulin D, Owen WF Jr, Winkelmayer WC, Tonelli M. A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int 2004; 66:1239-47.
11. Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol 2007; 99(6A):22C-31C.
12. Wakasugi H, Futami T, Muso E, Ono T, Sasayama S, Inui K. Thrombocytopenia and anemia induced by niceritrol used for amelioration of hyperphosphatemia in a hemodialysis patient. Nephron 2000; 86:97-8.